Igurati 25mg Tablet contains Iguratimod, a disease-modifying antirheumatic drug (DMARD) primarily indicated for the treatment of rheumatoid arthritis. Iguratimod exerts its therapeutic effect by inhibiting the production of pro-inflammatory cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor-alpha, thereby reducing inflammation and joint destruction. This immunomodulatory agent also suppresses immunoglobulin production and modulates T-cell activation, contributing to the attenuation of autoimmune responses. Igurati is typically prescribed as part of a comprehensive treatment regimen to improve joint function, decrease pain, and slow disease progression in patients with active rheumatoid arthritis. The recommended dosage is 25mg administered orally, usually once or twice daily, depending on clinical judgment. It is essential to monitor liver function tests and complete blood counts periodically during therapy due to potential hepatotoxicity and hematological adverse effects. Common side effects include gastrointestinal discomfort, elevated liver enzymes, and mild leukopenia. Igurati should be used with caution in patients with pre-existing liver disease or hematological abnormalities. It is contraindicated in pregnancy and lactation due to insufficient safety data. Patients are advised to adhere strictly to prescribed dosages and report any adverse reactions promptly to their healthcare provider.